UroAlert - GU Oncology Daily

July 09, 2026

Videos

Peer-to-Peer Clinical Conversations

Restricted Mean Survival Time Analysis of First-Line IO Combinations in Advanced RCC - Yudai Ishiyama

Yudai Ishiyama

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC.

View

ENVISION Trial Analysis: Reverse Thermal Gel with Mitomycin Outcomes by EORTC Risk Group – William Huang

William Huang

William Huang presents a post-hoc analysis from the ENVISION study evaluating ZUSDURI™, a reverse thermal gel mitomycin formulation, for intermediate-risk low-grade non-muscle-invasive bladder cancer.

View

Beyond the Abstracts

Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee - Beyond the Abstract

HER2 and Urothelial Carcinoma: Current Understanding and Future Directions - Beyond the Abstract

Conference Coverage

ASCO 2026: PROs from IMvigor011: A Phase 3 Study of ctDNA-Guided Adjuvant Atezolizumab vs Placebo in MIBC

AUA 2026: Impact of Increased H-1B Visa Cost on the Urology Workforce: A Simulation-Based Projection of the Urologist Shortage by 2035

AUA 2026: Intravesical Versus Intravenous Therapy of Camrelizumab in BCG-Unresponsive High-Risk NMIBC: Results from a Randomized Parallel-Cohort Phase I–II Study

AUA 2026: Evaluating Deep Early Tumor Shrinkage in Metastatic Upper Tract Urothelial Carcinoma Treated with Enfortumab Vedotin plus Pembrolizumab

APCCC 2026: Is There a Possibility to Make NGS Testing/results Widely Available?

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Renal Cancer

Prostate Cancer

Testicular Cancer

Login